211 related articles for article (PubMed ID: 35606813)
21. m6A Regulator-Associated Modification Patterns and Immune Infiltration of the Tumor Microenvironment in Hepatocarcinoma.
Li J; Wang W; Zhou Y; Liu L; Zhang G; Guan K; Cui X; Liu X; Huang M; Cui G; Sun R
Front Cell Dev Biol; 2021; 9():687756. PubMed ID: 34277630
[No Abstract] [Full Text] [Related]
22. M6A regulator-mediated immune infiltration and methylation modification in hepatocellular carcinoma microenvironment and immunotherapy.
Zhao K; Wei B; Zhang Y; Shi W; Zhang G; Wang Z
Front Pharmacol; 2022; 13():1052177. PubMed ID: 36438800
[No Abstract] [Full Text] [Related]
23. m6A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in hepatocellular carcinoma.
Huang X; Qiu Z; Li L; Chen B; Huang P
Aging (Albany NY); 2021 Aug; 13(16):20698-20715. PubMed ID: 34461607
[TBL] [Abstract][Full Text] [Related]
24. m6A Modification Patterns With Distinct Immunity, Metabolism, and Stemness Characteristics in Soft Tissue Sarcoma.
Huang ZD; Lin LL; Liu ZZ; Hu C; Gu HY; Wei RX
Front Immunol; 2021; 12():765723. PubMed ID: 35003079
[TBL] [Abstract][Full Text] [Related]
25. Prognostic N6-methyladenosine (m6A)-related lncRNA patterns to aid therapy in pancreatic ductal adenocarcinoma.
Wang Y; Ji Y; Xu Q; Huang W
Front Genet; 2022; 13():866340. PubMed ID: 36226185
[No Abstract] [Full Text] [Related]
26. Molecular Characteristics of m6A Regulators and Tumor Microenvironment Infiltration in Soft Tissue Sarcoma: A Gene-Based Study.
Xiao KW; Yang ZQ; Yan X; Liu ZB; Yang M; Guo LY; Cai L
Front Bioeng Biotechnol; 2022; 10():846812. PubMed ID: 35519620
[No Abstract] [Full Text] [Related]
27. Characterization of m6A regulator-mediated methylation modification patterns and tumor microenvironment infiltration in acute myeloid leukemia.
Han S; Qi J; Fang K; Wang H; Tang Y; Wu D; Han Y
Cancer Med; 2022 Mar; 11(5):1413-1426. PubMed ID: 35023630
[TBL] [Abstract][Full Text] [Related]
28. m6A modification patterns are associated with copy number burden and tumor immune landscape in thyroid cancer.
Cai L; Liu T; Hua H; Jiang X; Qian L
BMC Endocr Disord; 2023 Dec; 23(1):271. PubMed ID: 38057752
[TBL] [Abstract][Full Text] [Related]
29. Characterization of m6A methylation modifications in gastric cancer.
Yin W; Huo Z; Zuo J; Wang H; Chen B; Zhou L
Aging (Albany NY); 2024 Jan; 16(1):89-105. PubMed ID: 38206646
[TBL] [Abstract][Full Text] [Related]
30. The role of m6A-related genes in the prognosis and immune microenvironment of pancreatic adenocarcinoma.
Tang R; Zhang Y; Liang C; Xu J; Meng Q; Hua J; Liu J; Zhang B; Yu X; Shi S
PeerJ; 2020; 8():e9602. PubMed ID: 33062408
[TBL] [Abstract][Full Text] [Related]
31. An integrated model of N6-methyladenosine regulators to predict tumor aggressiveness and immune evasion in pancreatic cancer.
Zhou Z; Zhang J; Xu C; Yang J; Zhang Y; Liu M; Shi X; Li X; Zhan H; Chen W; McNally LR; Fung KM; Luo W; Houchen CW; He Y; Zhang C; Li M
EBioMedicine; 2021 Mar; 65():103271. PubMed ID: 33714027
[TBL] [Abstract][Full Text] [Related]
32. Constructing and validating of m6a-related genes prognostic signature for stomach adenocarcinoma and immune infiltration: Potential biomarkers for predicting the overall survival.
Yang J; Wu Z; Wu X; Chen S; Xia X; Zeng J
Front Oncol; 2022; 12():1050288. PubMed ID: 36620557
[TBL] [Abstract][Full Text] [Related]
33. Characterization of the m6A-Associated Tumor Immune Microenvironment in Prostate Cancer to Aid Immunotherapy.
Liu Z; Zhong J; Zeng J; Duan X; Lu J; Sun X; Liu Q; Liang Y; Lin Z; Zhong W; Wu W; Cai C; Zeng G
Front Immunol; 2021; 12():735170. PubMed ID: 34531875
[TBL] [Abstract][Full Text] [Related]
34. N6-methyladenosine RNA Methylation Correlates with Immune Microenvironment and Immunotherapy Response of Melanoma.
Wang G; Zeng D; Sweren E; Miao Y; Chen R; Chen J; Wang J; Liao W; Hu Z; Kang S; Garza LA
J Invest Dermatol; 2023 Aug; 143(8):1579-1590.e5. PubMed ID: 36842525
[TBL] [Abstract][Full Text] [Related]
35. N6-methyladenosine (m6A) regulatory gene divides hepatocellular carcinoma into three subtypes.
Wei J; Fang DL; Zhou W; He YF
J Gastrointest Oncol; 2021 Aug; 12(4):1860-1872. PubMed ID: 34532134
[TBL] [Abstract][Full Text] [Related]
36. m
Chong W; Shang L; Liu J; Fang Z; Du F; Wu H; Liu Y; Wang Z; Chen Y; Jia S; Chen L; Li L; Chen H
Theranostics; 2021; 11(5):2201-2217. PubMed ID: 33500720
[TBL] [Abstract][Full Text] [Related]
37. Development and validation of a novel N6-methyladenosine (m6A)-related multi- long non-coding RNA (lncRNA) prognostic signature in pancreatic adenocarcinoma.
Yuan Q; Ren J; Li L; Li S; Xiang K; Shang D
Bioengineered; 2021 Dec; 12(1):2432-2448. PubMed ID: 34233576
[TBL] [Abstract][Full Text] [Related]
38. Characterization of m6A methylation modifications and tumor microenvironment infiltration in thyroid cancer.
Ji FH; Yang Z; Sun C; Lowe S; Qiu XG
Clin Transl Oncol; 2023 Jan; 25(1):269-282. PubMed ID: 36163443
[TBL] [Abstract][Full Text] [Related]
39. N
Li C; Zhu M; Gao C; Lu F; Chen H; Liu J; Zhong W
Front Biosci (Landmark Ed); 2024 Jan; 29(1):33. PubMed ID: 38287827
[TBL] [Abstract][Full Text] [Related]
40. Identification of m6A modification patterns and RBM15 mediated macrophage phagocytosis in pancreatic cancer: An integrative analysis.
Wang W; He Y; Yao LC; Yuan Y; Lu C; Xiong LK; Ma P; Zhang YF; Yu KH; Tang ZG
Biochim Biophys Acta Mol Basis Dis; 2024 Jun; 1870(7):167304. PubMed ID: 38878830
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
